BGI didn’t infringe one Illumina patent, fails to invalidate another

The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Illumina gets $8m plus injunction from DNA sequencing suit

29 March 2022 DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.

Big Pharma

BGI secures appeal trial over Illumina DNA verdict

25 February 2021 Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.

Big Pharma

BGI counter sues Illumina for patent infringement

4 October 2019 A US subsidiary of Chinese genome sequencing company BGI has filed a patent infringement counterclaim against Illumina.